Get the Stockscreener App
10.24
1.92%
-0.20
After Hours:
10.24
Adaptive Biotechnologies Corp stock is traded at $10.24, with a volume of 1.70M.
It is down -1.92% in the last 24 hours and down -12.10% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
See More
Previous Close:
$10.44
Open:
$10.35
24h Volume:
1.70M
Relative Volume:
0.82
Market Cap:
$1.56B
Revenue:
$177.28M
Net Income/Loss:
$-195.24M
P/E Ratio:
-7.6418
EPS:
-1.34
Net Cash Flow:
$-114.54M
1W Performance:
-3.94%
1M Performance:
-12.10%
6M Performance:
+32.13%
1Y Performance:
+125.05%
1-Day Range:
$9.9551
$10.46
1-Week Range:
$9.9551
$10.85
52-Week Range:
$3.845
$12.43
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
10.24 | 1.59B | 177.28M | -195.24M | -114.54M | -1.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Initiated | Craig Hallum | Buy |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
Analyzing recovery setups for Adaptive Biotechnologies Corporation investorsBuy Zone Strategy with Pattern Recognition - Newser
How Adaptive Biotechnologies Corporation stock reacts to Fed policy changesVolume Based Swing Signal Prediction Map - Newser
Sentiment Turns Positive on Adaptive Biotechnologies Corporation — Reversal AheadEntry and Exit Strategy Optimizer Tool Tested - metal.it
BTIG Increases Price Target for Adaptive Biotechnologies (ADPT) to $13 - GuruFocus
How Efficient Is Adaptive Biotechnologies Corporation at Controlling Operating CostsPattern Recognition Based Market Move Prediction - Newser
Published on: 2025-07-29 02:45:46 - Newser
Why Adaptive Biotechnologies Corporation stock attracts strong analyst attentionFundamental + Technical Combined Watchlist - Newser
How does Adaptive Biotechnologies Corporation generate profit in a changing economyInvest confidently with real-time data analysis - jammulinksnews.com
Bank of New York Mellon Corp Has $2.66 Million Position in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) - Defense World
What catalysts could drive Adaptive Biotechnologies Corporation stock higher in 2025Breakout profit opportunities - jammulinksnews.com
Sectors Driving Future Growth for Adaptive Biotechnologies Corporation StockFree Stock Index Interpretation - Newser
New Product Launches: Will They Boost Adaptive Biotechnologies Corporation Stock in 2025Market Timing Advice - Newser
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics - Benzinga
U.S. Minimal Residual Disease Testing Market Trends Analysis Report 2025-2033 | Integration with Personalized Medicines, & Rising Incidence and Prevalence of Hematological Malignancies Fueling Growth - GlobeNewswire Inc.
Adaptive Biotechnologies' (NASDAQ:ADPT) investors will be pleased with their strong 161% return over the last year - Yahoo Finance
Victory Capital Management Inc. Has $13.11 Million Holdings in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) - Defense World
What analysts say about Adaptive Biotechnologies Corporation stockRecord-breaking capital gains - Autocar Professional
Adaptive Biotechnologies Corporation Stock Analysis and ForecastExplosive trading opportunities - jammulinksnews.com
How Adaptive Biotechnologies Corporation stock performs during market volatilityFree Access to Community with 300% Return - Newser
Adaptive Biotechnologies Corporation (ADPT) Rose on Solid Results - Yahoo.co
Is Adaptive Biotechnologies Corporation a good long term investmentExceptional earning trajectories - jammulinksnews.com
Principal Financial Group Inc. Purchases 141,691 Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) - Defense World
Cerity Partners LLC Sells 21,433 Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Teacher Retirement System of Texas Acquires New Position in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025 - The Manila Times
Adaptive Biotechnologies Corporation to Announce Second Quarter 2025 Financial Results on August 5, 2025 - Quiver Quantitative
What makes Adaptive Biotechnologies Corporation stock price move sharplyHigh Confidence Trade Setups - Newser
Wealth Enhancement Advisory Services LLC Invests $87,000 in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) - Defense World
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year? - Yahoo Finance
Adaptive Biotechnologies and Flatiron Health Collaborate to Integrate clonoSEQ® Test into OncoEMR® for Enhanced Blood Cancer Care - Quiver Quantitative
Adaptive Biotechnologies Corporation(NasdaqGS:ADPT) added to Russell 3000 Growth Index - MarketScreener
Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains? - Yahoo Finance
Craig-Hallum Initiates Coverage of Adaptive Biotechnologies (ADPT) stock, Gives Buy - Insider Monkey
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Cathie Wood's Ark Invest Adds Airbnb, AMD, Shopify To Portfolio, Slashes Stake In Circle Internet - Benzinga
Cathie Wood’s ARK buys BWX stock, sells Adaptive Biotech By Investing.com - Investing.com India
Cathie Wood’s ARK buys BWX stock, sells Adaptive Biotech - Investing.com
Adaptive Biotechnologies (ADPT) Initiates Coverage with Buy Rating | ADPT Stock News - GuruFocus
Adaptive Biotechnologies (ADPT) Sees Positive Growth Prospects | - GuruFocus
Assessing Adaptive Biotechnologies: Insights From 5 Financial Analysts - Nasdaq
Adaptive Biotechnologies (ADPT) Receives New Buy Rating and Pric - GuruFocus
Adaptive Biotechnologies reports annual meeting outcomes By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies reports annual meeting outcomes - Investing.com
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Bought by California State Teachers Retirement System - Defense World
Adaptive Biotechnologies at Goldman Sachs Conference: Strong Q1 Performance and Strategic Growth - Investing.com
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):